Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29277674 | 0.82 | NCF1 (0.43) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL16010143 | 0.81 | GAK (0.37) | AAK1SLC22A12RIPK2GAK | |
| SCHEMBL783960 | 0.81 | LMNA (0.44) | TSHRMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL16009379 | 0.81 | GAK (0.37) | AAK1GRM4GAK | |
| SCHEMBL16010147 | 0.78 | NCF1 (0.45) | NCF1HTTADRB2TSHRCYP2C19 | |
| SCHEMBL482068 | 0.76 | NCF1 (0.50) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL5953116 | 0.76 | ALDH1A1 (0.36) | CYP3A4TSHRCYP2C19MEN1ALDH1A1 | |
| SCHEMBL1164876 | 0.75 | PRKCI (0.40) | — | |
| SCHEMBL16150302 | 0.75 | ADORA2A (0.43) | ADRB2LMNAMAPTKMT2A | |
| SCHEMBL4434307 | 0.74 | CYP3A4 (0.44) | NCF1CYP3A4TSHRCYP2C19SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113957441-B | Etching solution and preparation method and application thereof | 光华科学技术研究院(广东)有限公司 | 2024-01-02 | — | — | CN | claimed |
| CN-113957441-A | Etching solution and preparation method and application thereof | 光华科学技术研究院(广东)有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-113957441-B | Etching solution and preparation method and application thereof | 光华科学技术研究院(广东)有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-115246813-A | High refractive index organic compound, cover layer material and light emitting element | 东丽先端材料研究开发（中国）有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-113957441-A | Etching solution and preparation method and application thereof | 光华科学技术研究院(广东)有限公司 | 2022-01-21 | — | — | CN | disclosed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2970312-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164596-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | NCF1 1023/4885LOXL2 1520/4885HTR1A 4254/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | NCF1 1023/4885LOXL2 1520/4885HTR1A 4254/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | NCF1 1023/4885LOXL2 1520/4885HTR1A 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.